SER Serina Therapeutics, Inc.: Enterprise Value to EBITDA Ratio

serinatherapeutics.com (SER) - corporate logo

The share price retrospective for Serina Therapeutics, Inc. (SER) demonstrates a value of 0.00, driven by the monetization of exclusive CNS drug delivery technologies through royalties and licensing fees. Stability in these metrics is supported by streamlined polymer raw material supply chains and a network of external laboratories. The business's success is solidified by a distinguished scientific leadership team, which has ensured patent transparency and the trust of global investors.

SER Serina: Business Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/16/2026

Serina Therapeutics Inc (SER) - metric breakdowns and financial figures

- current price and projected stock value:
Initial company analysis:Serina Pharma SER
Original product of Serina Therapeutics

The development of innovative polymer drug delivery systems creates long-term patent capitalization potential for Serina Therapeutics, Inc. (SER). By analyzing the EV/EBITDA multiple trend, an investor assesses the enterprise value relative to operating profit before depreciation and amortization. This metric determines asset management efficiency and allows for the timely identification of either company undervaluation or a critical increase in debt load amid drug development.

Main competitors

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jazz Pharmaceuticals plc JAZZ|CYTK: Enterprise Value to Operating Income Before Depreciation|PTC Bio - EV/EBITDA Multiple|Company Value to EBITDA Scholar Rock Corp|CNTA (Centessa Pharmaceuticals plc) - Enterprise Value to EBITDA Ratio|Dyne Corp - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Edgewise Therapeutics|RAPP: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alumis Pharma (ALMS)|ZVRA - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Contineum Pharma CTNM|Larimar Corp - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CAPR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Entrada Therapeutics|PTHS: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple MediciNova, Inc. MNOV|Enterprise Value to EBITDA Ratio BTAI|promisneurosciences.com - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple APUS|EV/EBITDA Multiple AEON Biopharma, Inc. (AEON)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NLS Pharma NLSP|Total Company Value to Operating Income Before Depreciation Ratio Bionomics Limited (BNOX)|FSD Pharma Inc. - EV/EBITDA Multiple|RETA - EV/EBITDA Multiple